About takeda pharmaceutical co. ltd. - TAK
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
TAK At a Glance
Takeda Pharmaceutical Co., Ltd.
4-1-1 Dosho-machi
Osaka, Osaka 540-8645
| Phone | 81-6-6204-2111 | Revenue | 30.05B | |
| Industry | Pharmaceuticals: Major | Net Income | 707.96M | |
| Sector | Health Technology | 2025 Sales Growth | 1.922% | |
| Fiscal Year-end | 03 / 2026 | Employees | 47,455 | |
| View SEC Filings |
TAK Valuation
| P/E Current | 171.53 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 66.325 |
| Price to Sales Ratio | 1.589 |
| Price to Book Ratio | 1.009 |
| Price to Cash Flow Ratio | 7.56 |
| Enterprise Value to EBITDA | 8.693 |
| Enterprise Value to Sales | 2.635 |
| Total Debt to Enterprise Value | 0.43 |
TAK Efficiency
| Revenue/Employee | 633,289.189 |
| Income Per Employee | 14,918.449 |
| Receivables Turnover | 6.197 |
| Total Asset Turnover | 0.308 |
TAK Liquidity
| Current Ratio | 1.006 |
| Quick Ratio | 0.52 |
| Cash Ratio | 0.154 |
TAK Profitability
| Gross Margin | 53.589 |
| Operating Margin | 13.697 |
| Pretax Margin | 3.909 |
| Net Margin | 2.356 |
| Return on Assets | 0.726 |
| Return on Equity | 1.499 |
| Return on Total Capital | 0.88 |
| Return on Invested Capital | 0.898 |
TAK Capital Structure
| Total Debt to Total Equity | 73.375 |
| Total Debt to Total Capital | 42.321 |
| Total Debt to Total Assets | 35.714 |
| Long-Term Debt to Equity | 64.53 |
| Long-Term Debt to Total Capital | 37.22 |